Expert Point of View: Mark Crowther, MD

Get Permission

Mark Crowther, MD

Commenting on the AALL03N1 study, press conference moderator Mark Crowther, MD, of McMaster University, Hamilton, Ontario, Canada, said: “This study is extremely important. We have many presentations on new and novel therapies that are expensive, complex, and revolutionary. But if patients don’t take their drugs as prescribed, these drugs won’t be effective.”

“It’s great to have advances in therapy, but we need to spend some time on how to use our medications appropriately. We have to ascertain if a patient fails because he or she didn’t take [his or her] medication,” he said. ■

Disclosure: Dr. Crowther reported no potential conflicts of interest.


Related Articles

Self-Reports Overestimate Mercaptopurine Intake in Childhood Acute Lymphoblastic Leukemia

Mercaptopurine is critical for maintaining remission in childhood acute lymphoblastic leukemia (ALL). However, a study has shown that overreporting of intake is common, and self-reports of intake are not as reliable as electronic reporting.1

About 86% of parents and children overreported the...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.